Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2014

01-08-2014 | Review

The prognostic value of autophagy-related markers beclin-1 and microtubule-associated protein light chain 3B in cancers: a systematic review and meta-analysis

Authors: Yuyu He, Xianda Zhao, Narishka Roz Subahan, Lifang Fan, Jun Gao, Honglei Chen

Published in: Tumor Biology | Issue 8/2014

Login to get access

Abstract

Use of the autophagy-related markers beclin-1 (BECN1) and microtubule-associated protein light chain 3B (LC3B) as prognostic markers has been extensively investigated in various kinds of cancers. However, their prognostic roles are still controversial and not firmly validated. We systematically reviewed the evidence from various studies concerning the relationship between BECN1 and LC3B expression in cancers and overall survival (OS)/disease-free survival (DFS) to elucidate this issue. PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure (CNKI) were searched in July 2013 (then updated in April 2014) to identify eligible cohort studies that reported associations between BECN1 or LC3B expression and OS/DFS in cancer patients. Combined hazard ratios (HRs) with 95 % confidence intervals (95 % CIs) were pooled using fixed-effects or random-effects models according to heterogeneity in different groups. A total of 23 studies in distinct cancers were eligible for systematic review and meta-analysis. Our pooled results identified that a high expression of BECN1 is associated with favorable OS in gastric cancer (HR = 0.49, 95 % CI = 0.34–0.72) and lymphoma (HR = 0.25, 95 % CI = 0.11–0.57), whereas a high expression of LC3B predicts adverse OS in breast cancer (HR = 1.98, 95 % CI = 1.25–3.13). This systematic review and meta-analysis indicated that the autophagy-related marker BECN1 might be a predictive factor of favorable prognosis in gastric cancer, breast cancer, and lymphoma and LC3B might predict unfavorable prognosis of breast cancer. Nevertheless, due to the limited number and retrospective design of the original studies, more powerful prospective cohorts are required to verify these conclusions.
Appendix
Available only for authorised users
Literature
1.
Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013;368:651–62.PubMedCrossRef
2.
3.
Zhao X, He Y, Chen H. Autophagic tumor stroma: mechanisms and roles in tumor growth and progression. Int J Cancer. 2013;132:1–8.PubMedCrossRef
4.
Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol. 2012;7:423–67.PubMedCrossRef
5.
6.
Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, Atomi Y, et al. Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res. 2007;67:9677–84.PubMedCrossRef
7.
8.
Sun WL, Chen J, Wang YP, Zheng H. Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy. 2011;7:1035–44.PubMedCrossRef
9.
Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007;21:1367–81.PubMedCentralPubMedCrossRef
10.
Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009;137:1062–75.PubMedCentralPubMedCrossRef
11.
Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006;10:51–64.PubMedCentralPubMedCrossRef
12.
Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8:445–544.PubMedCentralPubMedCrossRef
13.
Zalckvar E, Berissi H, Mizrachy L, Idelchuk Y, Koren I, Eisenstein M, et al. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from bcl-xl and induction of autophagy. EMBO Rep. 2009;10:285–92.PubMedCentralPubMedCrossRef
14.
15.
Cao Y, Klionsky DJ. Physiological functions of Atg6/beclin 1: a unique autophagy-related protein. Cell Res. 2007;17:839–49.PubMedCrossRef
16.
Weidberg H, Shvets E, Shpilka T, Shimron F, Shinder V, Elazar Z. LC3 and GATE-16/GABARAP subfamilies are both essential yet act differently in autophagosome biogenesis. EMBO J. 2010;29:1792–802.PubMedCentralPubMedCrossRef
17.
18.
Zhou WH, Tang F, Xu J, Wu X, Yang SB, Feng ZY, et al. Low expression of beclin 1, associated with high Bcl-xL, predicts a malignant phenotype and poor prognosis of gastric cancer. Autophagy. 2012;8:389–400.PubMedCrossRef
19.
Li BX, Li CY, Peng RQ, Wu XJ, Wang HY, Wan DS, et al. The expression of beclin 1 is associated with favorable prognosis in stage IIIB colon cancers. Autophagy. 2009;5:303–6.PubMedCrossRef
20.
Won KY, Kim GY, Kim YW, Song JY, Lim SJ. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum Pathol. 2010;41:107–12.PubMedCrossRef
21.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.PubMedCentralPubMedCrossRef
22.
Wells GA. SB, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2000.
23.
Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.PubMedCentralPubMedCrossRef
24.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedCentralPubMedCrossRef
25.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.PubMedCrossRef
26.
Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002;21:3337–51.PubMedCrossRef
27.
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Fixed-effect versus random-effects models. In: Introduction to meta-analysis. Chichester: Wiley; 2009. p. 77–86.CrossRef
28.
Chen YB, Hou JH, Feng XY, Chen S, Zhou ZW, Zhang XS, et al. Decreased expression of beclin 1 correlates with a metastatic phenotypic feature and adverse prognosis of gastric carcinomas. J Surg Oncol. 2012;105:542–7.PubMedCrossRef
29.
Geng QR, Xu DZ, He LJ, Lu JB, Zhou ZW, Zhan YQ, et al. Beclin-1 expression is a significant predictor of survival in patients with lymph node-positive gastric cancer. PLoS One. 2012;7:e45968.PubMedCentralPubMedCrossRef
30.
Li J, Yu G, Wang J, Pan J, Liu K, Li P, et al. The expression and prognostic value of beclin 1 and PTEN in gastric carcinoma. Chin J Dig. 2012;32:170–4.
31.
Yu M, Gou WF, Zhao S, Xiao LJ, Mao XY, Xing YN, et al. Beclin 1 expression is an independent prognostic factor for gastric carcinomas. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:1071–83.CrossRef
32.
Kim S, Jung WH, Koo JS. Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer. Tumour Biol J Int Soc Oncodev Biol Med. 2012;33:1681–94.CrossRef
33.
Zhao H, Yang M, Zhao J, Wang J, Zhang Y, Zhang Q. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer. Med Oncol. 2013;30:475.PubMedCrossRef
34.
Choi J, Jung W, Koo JS. Expression of autophagy-related markers beclin-1, light chain 3a, light chain 3b and p62 according to the molecular subtype of breast cancer. Histopathology. 2013;62:275–86.PubMedCrossRef
35.
Chen S: Autophagy in breast cancer patients with residual tumors after neo-adjuvant chemotherapy and its correlation with patients outcome. Fudan University 2012.
36.
Chen S, Jiang YZ, Huang L, Zhou RJ, Yu KD, Liu Y, et al.: The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 2013.
37.
Choi JH, Cho YS, Ko YH, Hong SU, Park JH, Lee MA. Absence of autophagy-related proteins expression is associated with poor prognosis in patients with colorectal adenocarcinoma. Gastroenterol Res Pract. 2014;2014:179586.PubMedCentralPubMedCrossRef
38.
Koukourakis MI, Giatromanolaki A, Sivridis E, Pitiakoudis M, Gatter KC, Harris AL. Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia. Br J Cancer. 2010;103:1209–14.PubMedCentralPubMedCrossRef
39.
Li BX, Zhang X. Mechanism of beclin1 as a favorable molecules marker is that beclin1 inhibits tumor proliferation and cell cycle arrest in stage iiib colon cancers. Chin J Clin. 2010;4:395–401.
40.
Myung Park J, Huang S, Wu TT, Foster NR, Sinicrope FA. Prognostic impact of beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther. 2013;14:100–7.CrossRef
41.
Nicotra G, Mercalli F, Peracchio C, Castino R, Follo C, Valente G, et al. Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas. Mod Pathol. 2010;23:937–50.PubMedCrossRef
42.
Huang JJ, Li HR, Huang Y, Jiang WQ, Xu RH, Huang HQ, et al. Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Autophagy. 2010;6:777–83.PubMedCrossRef
43.
Huang JJ, Zhu YJ, Lin TY, Jiang WQ, Huang HQ, Li ZM. Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Hum Pathol. 2011;42:1459–66.PubMedCrossRef
44.
Dong M, Wan XB, Yuan ZY, Wei L, Fan XJ, Wang TT, et al. Low expression of beclin 1 and elevated expression of HIF-1alpha refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer. Med Oncol. 2013;30:355.PubMedCrossRef
45.
Kim KM, Yu TK, Chu HH, Park HS, Jang KY, Moon WS, et al. Expression of er stress and autophagy-related molecules in human non-small cell lung cancer and premalignant lesions. Int J Cancer. 2012;131:E362–70.PubMedCrossRef
46.
Xiao Y, Long C, Zhang M, Luo Y, Hu Y. Expression of beclin-1 in non-small cell lung cancer and its clinical significance. J Third Mil Med Univ. 2013;12:1271–3.
47.
Zhou W, Yue C, Deng J, Hu R, Xu J, Feng L, et al. Autophagic protein beclin 1 serves as an independent positive prognostic biomarker for non-small cell lung cancer. PLoS One. 2013;8:e80338.PubMedCentralPubMedCrossRef
48.
Lebovitz CB, Bortnik SB, Gorski SM. Here, there be dragons: charting autophagy-related alterations in human tumors. Clin Cancer Res. 2012;18:1214–26.PubMedCrossRef
49.
Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (remark): explanation and elaboration. PLoS Med. 2012;9:e1001216.PubMedCentralPubMedCrossRef
50.
Kuma A, Matsui M, Mizushima N. LC3, an autophagosome marker, can be incorporated into protein aggregates independent of autophagy: caution in the interpretation of LC3 localization. Autophagy. 2007;3:323–8.PubMedCrossRef
51.
Zhu JH, Horbinski C, Guo F, Watkins S, Uchiyama Y, Chu CT. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am J Pathol. 2007;170:75–86.PubMedCentralPubMedCrossRef
52.
Scarlatti F, Maffei R, Beau I, Codogno P, Ghidoni R. Role of non-canonical beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ. 2008;15:1318–29.PubMedCrossRef
Metadata
Title
The prognostic value of autophagy-related markers beclin-1 and microtubule-associated protein light chain 3B in cancers: a systematic review and meta-analysis
Authors
Yuyu He
Xianda Zhao
Narishka Roz Subahan
Lifang Fan
Jun Gao
Honglei Chen
Publication date
01-08-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2060-4

Other articles of this Issue 8/2014

Tumor Biology 8/2014 Go to the issue

Research Article

Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma

Research Article

Functional IRGM polymorphism is associated with language impairment in glioma and upregulates cytokine expressions

Research Article

PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression

Research Article

Overexpression of SOX2 promotes migration, invasion, and epithelial-mesenchymal transition through the Wnt/β-catenin pathway in laryngeal cancer Hep-2 cells

Review

S100A2 protein and non-small cell lung cancer. The dual role concept

Research Article

LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits